

**In the Claims:**

Please cancel claims 6-7. Please amend claim 1. Please add new claims 8-22. The claims are as follows.

1. (Currently amended) A method of treating inflammatory disorders in a mammal comprising administering to said mammal a combination of: (i) a standard therapeutic dose of a COX2 inhibitor selected from the group consisting of celecoxib and rofecoxib[[,]] and (ii) low dose aspirin in ~~the~~ an amount of 70-85 mg, ~~and (iii) antioxidant flavanoids, flavonoids or isoflavones.~~

2-5. (Canceled)

5. (Previously presented) The method of claim 1, wherein the low dose aspirin is in an enteric coated formulation.

6-7. (Canceled)

8. (New) The method of claim 1, wherein the combination is a therapeutic composition comprising the COX2 inhibitor and the low dose aspirin.

9. (New) The method of claim 8, wherein the therapeutic composition is in an enteric coated formulation.

10. (New) The method of claim 1, wherein the combination further comprises an antioxidant selected from the group consisting of a flavanoid, a flavonoid, an isoflavone, and combinations thereof.

11. (New) The method of claim 10, wherein the antioxidant comprises the flavanoid.

12. (New) The method of claim 10, wherein the antioxidant comprises the flavonoid.

13. (New) The method of claim 10, wherein the antioxidant comprises the isoflavone.

14. (New) The method of claim 10, wherein the combination is a therapeutic composition comprising the COX2 inhibitor, the low dose aspirin, and the antioxidant.

15. (New) The method of claim 14, wherein the therapeutic composition is in an enteric coated formulation.

16. (New) A pharmaceutical composition, comprising a therapeutic composition for treating inflammatory disorders in a mammal, said therapeutic composition comprising (i) a standard therapeutic dose of a COX2 inhibitor selected from the group consisting of celecoxib and rofecoxib and (ii) low dose aspirin in an amount of 70-85 mg.

17. (New) The pharmaceutical composition of claim 16, wherein the therapeutic composition is

in an enteric coated formulation.

18. (New) The pharmaceutical composition of claim 16, wherein the therapeutic composition further comprises an antioxidant selected from the group consisting of a flavanoid, a flavonoid, an isoflavone, and combinations thereof.

19. (New) The pharmaceutical composition of claim 18, wherein the antioxidant comprises the flavanoid.

20. (New) The pharmaceutical composition of claim 18, wherein the antioxidant comprises the flavonoid.

21. (New) The pharmaceutical composition of claim 18, wherein the antioxidant comprises the isoflavone.

22. (New) The pharmaceutical composition of claim 18, wherein the therapeutic composition is in an enteric coated formulation.